B
Beijing Tongli Haiyuan Biotechnology
Established a stable library of cell lines using GE Wave, GMP-grade production environment
About Beijing Tongli Haiyuan Biotechnology
T L Biotechnology is a pioneering company in the biotechnology sector, headquartered in Beijing, China, with a research center in Germany. The company specializes in the development and production of recombinant proteins, monoclonal antibodies, and sorting reagents, among other products. T L Biotechnology serves a diverse range of clients, including research institutions, pharmaceutical companies, and healthcare providers. Operating in the global biotechnology market, the company leverages its proprietary recombinant protein production platform and GMP-grade production environment to ensure high batch consistency and safety.
The business model of T L Biotechnology revolves around both product sales and customized services. The company generates revenue by selling its biotechnology products, such as recombinant proteins and sorting reagents, and by offering tailored solutions to meet specific client needs. This includes large-scale production capacities ranging from 5L to 500L and one-stop protein customization services.
T L Biotechnology's competitive advantage lies in its more than 10 years of experience in recombinant protein research, high success rate of expression, and convenient separation operations. The company is committed to maintaining high purity and bioactivity in its products, ensuring they meet the stringent requirements of its clients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2025 | $0 | — | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Mar 2023 | $14M | $55M | Harvest Capital · Fortune Venture · Zhiheng (Yantai) | ↗ |
Growth signals
Latest recorded traffic for Beijing Tongli Haiyuan Biotechnology is 270 monthly website visits. Beijing Tongli Haiyuan Biotechnology's team declined 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beijing Tongli Haiyuan Biotechnology in its local ecosystem
The Beijing Tongli Haiyuan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- HCHarvest Capital
Fortune Venture- Z(Zhiheng (Yantai)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beijing Tongli Haiyuan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beijing Tongli Haiyuan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









